Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

NCT01217229 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01217229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01217229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2011
Completion date
April 26, 2012
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma